Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity

Recruiting now · Phase 2

Conditions studied: Cisplatin Nephrotoxicity, Nephrotoxicity

In brief

To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes

Key facts

Study ID

NCT07564479

Run by

Minia University

People needed

50

Starts

2026-03-10

Expected to finish

2027-06-01

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years. Histologically confirmed solid malignancy. Planned treatment with cisplatin starting from a dose of 60 mg/m2 per cycle (21-28 days each or fractionated).
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Baseline serum creatinine within normal range or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2.
• Ability to provide informed consent.

You may not qualify if…

• Pre existing renal impairment (eGFR < 60〖" mL/min/1.73 m" 〗\^2or serum creatinine > 1.5 × upper limit of normal).
• Concomitant use of known nephrotoxic drugs that cannot be stopped (e.g., aminoglycosides, amphotericin B, high dose NSAIDs).
• Uncontrolled hypertension, decompensated heart failure, or severe hepatic impairment.
• Known allergy or intolerance to ALA. Pregnancy or lactation. Participation in another interventional clinical trial.

Where it is running

• Minia University Hospital — Minya, Minya Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.